Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors), By Region, And Segment Forecasts, 2019 - 2025

Published: Feb, 2019 | Pages: 80 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global breast cancer drug market size is expected to reach USD 38.4 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.7% during the forecast period. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth.

Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies.

With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent's specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy.

F. Hoffman-La Roche Ltd leads the breast cancer drugs market with Herceptin, Perjeta, and Kadcyla. However, rapid advancements in biosimilars with a goal to offer cost effective alternatives to patients is anticipated to put pressure on this space. For instance, in December 2017, the Food and Drug Administration (FDA) approved the first biosimilar of trastuzumab for HER2+ breast cancer.

Further key findings from the report suggest:

• HER2 inhibitors is expected to be the most preferred drug class segment over the forecast period, owing to their high specificity as they are subclass of target therapy

• CDK 4/6 inhibitor is expected to be the fastest growing segment over the forecast period. There are currently more than 45 CDK 4/6 inhibitor drug candidates in pipeline

• North America held the largest market share in 2017 owing to the factors such as the presence of key manufacturers in the country, high awareness and adoption, and well-established healthcare infrastructure among others

• Europe was estimated to be the second largest regional segment in 2017 due to increasing incidence of breast cancer and growing R&D investments

• Asia Pacific is anticipated to witness healthy growth over the next decade due to increasing incidence of breast cancer, rise in awareness about early diagnosis in emerging countries such as China and India.

• Companies such as F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Company dominated the breast cancer drugs market

• The market is lucrative and competitive in nature as manufacturers engage in new product development to increase their product penetration. Moreover, they are entering into collaborations and partnerships to enhance their product portfolio.

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Data Analysis

Chapter 2 Executive Summary
                 2.1 Market Snapshot

Chapter 3 Breast cancer drug Market Variables, Trends & Scope
                 3.1 Market segmentation & scope
                     3.1.1 Market Driver Analysis
                         3.1.1.1 Increased incidence and prevalence rate of cancer worldwide
                         3.1.1.2 High investments in R & D
                         3.1.1.3 Increasing preference for targeted therapy approach in breast cancer treatment
                         3.1.1.4 Rise in the number of pipeline drugs.
                         3.1.1.5 Advancement in Cancer biology & pharmacology
                     3.1.2 Market Restrain Analysis
                         3.1.2.1 Stringent regulatory guidelines
                         3.1.2.2 Expiry of patented drugs
                         3.1.2.3 Complications associated with chemotherapy
                 3.2 Penetration & growth prospect mapping
                 3.3 Breast cancer drug - SWOT Analysis, By Factor (political & legal, economic and technological)
                 3.4 Industry Analysis - Porter's

Chapter 4 Breast cancer drug: Type Scope Estimates & Trend Analysis
                 4.1 Breast cancer drug market: application scope movement analysis
                 4.2 HER2 inhibitor
                     4.2.1 HER2 inhibitor market, 2014 - 2025 (USD Million)
                 4.3 Mitotic inhibitor
                     4.3.1 Mitotic inhibitor market, 2014 - 2025 (USD Million)
                 4.4 Anti-metabolites
                     4.4.1 Anti- metabolites market, 2014 - 2025 (USD Million)
                 4.5 Aromatase inhibitor
                     4.5.1 Aromatase inhibitor market, 2014 - 2025 (USD Million)
                 4.6 CDK 4/6 inhibitor
                     4.6.1 CDK 4/6 inhibitor market, 2014 - 2025 (USD Million)
                 4.7 Hormonal receptor
                     4.7.1 Hormonal receptor market, 2014 - 2025 (USD Million)

Chapter 5 Breast cancer drug: Regional Estimates & Trend Analysis 
                 5.1 Breast cancer drug market share by region, 2016 & 2025
                 5.2 North America
                     5.2.1 North America Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.2.2 U.S.
                         5.2.2.1 U.S. Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.2.3 Canada
                         5.2.3.1 Canada Breast cancer drug market, 2014 - 2025 (USD Million)
                 5.3 Europe
                     5.3.1 Europe Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.3.2 Germany
                         5.3.2.1 Germany Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.3.3 U.K.
                         5.3.3.1 U.K. Breast cancer drug market, 2014 - 2025 (USD Million)
                 5.4 Asia Pacific
                     5.4.1 Asia Pacific Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.4.2 China
                         5.4.2.1 China Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.4.3 Japan
                         5.4.3.1 Japan Breast cancer drug market, 2014 - 2025 (USD Million)
                 5.5 Latin America
                     5.5.1 Latin America Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.5.2 Brazil
                         5.5.2.1 Brazil Breast cancer drug market, 2014 - 2025 (USD Million)
                 5.6 Middle East and Africa
                     5.6.1 Middle East and Africa Breast cancer drug market, 2014 - 2025 (USD Million)
                     5.6.2 South Africa
                         5.6.2.1 South Africa Breast cancer drug market, 2014 - 2025 (USD Million)

Chapter 6 Competitive Landscape
                 6.1 Strategy framework
                 6.2 Market participation categorization
                     6.2.1 Novartis AG
                         6.2.1.1 Company overview
                         6.2.1.2 Financial performance
                         6.2.1.3 Technique benchmarking
                         6.2.1.4 Strategic initiatives
                     6.2.2 Pfizer Inc.
                         6.2.2.1 Company overview
                         6.2.2.2 Financial performance
                         6.2.2.3 Technique benchmarking
                         6.2.2.4 Strategic initiatives
                     6.2.3 Merck & Co Inc.
                         6.2.3.1 Company overview
                         6.2.3.2 Financial performance
                         6.2.3.3 Technique benchmarking
                         6.2.3.4 Strategic initiatives
                     6.2.4 Janssen Global Services LLC
                         6.2.4.1 Company overview
                         6.2.4.2 Financial performance
                         6.2.4.3 Technique benchmarking
                         6.2.4.4 Strategic initiatives
                     6.2.5 Celgene Corporation
                         6.2.5.1 Company overview
                         6.2.5.2 Financial performance
                         6.2.5.3 Technique benchmarking
                         6.2.5.4 Strategic initiatives
                     6.2.6 Astellas Pharma Inc.
                         6.2.6.1 Company overview
                         6.2.6.2 Financial performance
                         6.2.6.3 Technique benchmarking
                         6.2.6.4 Strategic initiatives
                     6.2.7 Genzyme Corporation
                         6.2.7.1 Company overview
                         6.2.7.2 Financial performance
                         6.2.7.3 Technique benchmarking
                         6.2.7.4 Strategic initiatives
                     6.2.8 F. Hoffman-La Roche Pvt. Ltd
                         6.2.8.1 Company overview
                         6.2.8.2 Financial performance
                         6.2.8.3 Technique benchmarking
                         6.2.8.4 Strategic initiatives
                     6.2.9 AstraZeneca
                         6.2.9.1 Company overview
                         6.2.9.2 Financial performance
                         6.2.9.3 Technique benchmarking
                         6.2.9.4 Strategic initiatives
                     6.2.10 AbbVie, Inc.
                         6.2.10.1 Company overview
                         6.2.10.2 Financial performance
                         6.2.10.3 Technique benchmarking
                         6.2.10.4 Strategic initiatives
                     6.2.11 Genentech, Inc.
                         6.2.11.1 Company overview
                         6.2.11.2 Financial performance
                         6.2.11.3 Technique benchmarking
                         6.2.11.4 Strategic initiatives
                     6.2.12 MacroGenics Inc.
                         6.2.12.1 Company overview
                         6.2.12.2 Financial performance
                         6.2.12.3 Technique benchmarking
                         6.2.12.4 Strategic initiatives
                     6.2.13 Celldex Therapeutics.
                         6.2.13.1 Company overview
                         6.2.13.2 Financial performance
                         6.2.13.3 Technique benchmarking
                         6.2.13.4 Strategic initiatives
                     6.2.14 Onyx Pharmaceuticals, Inc.
                         6.2.14.1 Company overview
                         6.2.14.2 Financial performance
                         6.2.14.3 Technique benchmarking
                         6.2.14.4 Strategic initiatives
                     6.2.15 BioNumerik Pharmaceuticals Inc.
                         6.2.15.1 Company overview
                         6.2.15.2 Financial performance
                         6.2.15.3 Technique benchmarking
                         6.2.15.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation 
TABLE 2 HER2 inhibitor drugs
TABLE 3 Herceptin drugs 
TABLE 4 Herceptin drugs 
TABLE 5 Hormone Receptor drugs 
TABLE 6 Perjeta drugs 
TABLE 7 Kadcyla drugs
TABLE 8 Mitotic inhibitor drugs 
TABLE 9 Halaven drug 
TABLE 10 Taxotere drug 
TABLE 11 Ixempra drugs
TABLE 12 Anti-metabolites drugs 
TABLE 13 Aromatase inhibitors drugs 
TABLE 14 Hormone Receptor drugs 
TABLE 15 Aromasin drugs 
TABLE 16 Arimidex drug 
TABLE 17 Ibrance drug 
TABLE 18 Afinitor drug 
TABLE 19 Hormone Receptor drugs 
TABLE 20 Zoladex drug 
TABLE 21 Faslodex drug 
TABLE 22 Fareston drugs 
TABLE 23 North America breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 24 U.S. breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 25 Canada breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 26 Europe breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 27 U.K. breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 28 Germany breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 29 Asia Pacific breast cancer drug market estimates and forecasts, by type, 2014 - 2025(USD Million) 
TABLE 30 Japan breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 31 China breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 32 India breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 33 Latin America breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 34 Brazil breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 35 Mexico breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)
TABLE 36 MEA breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million) 
TABLE 37 South Africa breast cancer drug market estimates and forecasts, by type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process 
FIG. 2 Information procurement 
FIG. 3 Value chain based sizing & forecasting 
FIG. 4 QFD modeling for market share assessment 
FIG. 5 Market Summary 
FIG. 6 Market trends & outlook 
FIG. 7 Market segmentation & scope 
FIG. 8 Market driver relevance analysis (Current & future impact) 
FIG. 9 R & D Spending's (2015 - 16) 
FIG. 10 Breast Cancer pipeline drugs 
FIG. 11 Market restraint relevance analysis (Current & future impact) 
FIG. 12 Penetration & growth prospect mapping 
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological) 
FIG. 14 Porter's Five Forces Analysis 
FIG. 15 Breast Cancer Drug market type of synthesis outlook key takeaways 
FIG. 16 Breast Cancer Drug market: Type movement analysis 
FIG. 17 Global HER2 inhibitorsmarket, 2014 - 2025 (USD Million) 
FIG. 18 Global antimetabolites market, 2014 - 2025 (USD Million) 
FIG. 19 Global mitotic inhibitors market, 2014 - 2025 (USD Million) 
FIG. 20 Global CDK 4/6 inhibitors market, 2014 - 2025 (USD Million) 
FIG. 21 Global hormone receptor market, 2014 - 2025 (USD Million) 
FIG. 22 Regional market place: Key takeaways
FIG. 23 Regional outlook, 2015 & 2024 5
FIG. 24 North America Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 25 U.S. Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 26 Canada Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 27 Europe Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 28 U.K. Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 29 Germany Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 30 Asia-Pacific Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 31 Japan Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 32 China Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 33 India Breast Cancer Drug market, 2014 - 2025 (USD Million)
FIG. 34 Latin America Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 35 Brazil Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 36 Mexico Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 37 MEA Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 38 South Africa Breast Cancer Drug market, 2014 - 2025 (USD Million) 
FIG. 39 Strategy framework
FIG. 40 Participant categorization